SRR603752
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.469
- KRAS_SIGNALING_DN+0.397
- INFLAMMATORY_RESPONSE+0.344
- IL6_JAK_STAT3_SIGNALING+0.307
- APICAL_SURFACE+0.290
- ANGIOGENESIS+0.274
- HEDGEHOG_SIGNALING+0.236
- INTERFERON_GAMMA_RESPONSE+0.236
- COAGULATION+0.231
- SPERMATOGENESIS+0.218
Top 10 suppressed
- MYC_TARGETS_V1-0.553
- DNA_REPAIR-0.501
- E2F_TARGETS-0.441
- PROTEIN_SECRETION-0.429
- G2M_CHECKPOINT-0.399
- MYC_TARGETS_V2-0.367
- OXIDATIVE_PHOSPHORYLATION-0.358
- UNFOLDED_PROTEIN_RESPONSE-0.353
- NOTCH_SIGNALING-0.336
- MTORC1_SIGNALING-0.319
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR608368 | GTEX | — | 0.968 |
| 2 | SRR1418283 | GTEX | — | 0.925 |
| 3 | SRR1470902 | GTEX | — | 0.916 |
| 4 | SRR1391598 | GTEX | — | 0.911 |
| 5 | SRR604528 | GTEX | — | 0.909 |
| 6 | SRR1489971 | GTEX | — | 0.903 |
| 7 | BS_2SHWPB5P | ganglioneuroblastoma | — | 0.900 |
| 8 | SRR1478946 | GTEX | — | 0.896 |
| 9 | SRR1315866 | GTEX | — | 0.893 |
| 10 | MDT-AP-0746 | Med | Medulloblastoma | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.469 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.397 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.344 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.307 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.274 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.236 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.236 | Idelalisib | — uncovered |
| COAGULATION | 0.231 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.218 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.216 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.212 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.202 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.192 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.169 | Inavolisib | — uncovered |
| MYOGENESIS | 0.159 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.147 | Inavolisib | — uncovered |
| APOPTOSIS | 0.138 | Idelalisib | — uncovered |
| COMPLEMENT | 0.136 | Inavolisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |